Secukinumab is Dominant Vs. TNF-Inhibitors in the Treatment of Active Ankylosing Spondylitis- Results from a Turkish Cost-Effectiveness Model

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.768
https://www.valueinhealthjournal.com/article/S1098-3015(17)31102-6/fulltext
Title : Secukinumab is Dominant Vs. TNF-Inhibitors in the Treatment of Active Ankylosing Spondylitis- Results from a Turkish Cost-Effectiveness Model
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31102-6&doi=10.1016/j.jval.2017.08.768
First page : A534
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 733
Categories :
Tags :
Regions :
ViH Article Tags :